doi:10.5009/gnl18490 Vukojevi J, Vrdoljak B, Malekinui D, et al
Among participants with prediabetes at baseline, normoglycemia by 15 months was achieved in 87.7% of those who received cagrilintidesemaglutide versus 32.2% of those who received placebo
One notable finding from meta-analyses: cagrilintide demonstrated the lowest odds ratios for nausea, vomiting, and diarrhea when compared to other incretin-based therapies including semaglutide and tirzepatide
For patients without clear indication for b12 supplementation, using a compounded combination means paying extra for an additive that may provide no benefit
The primary antibodies used are as follows: P53 (Proteintech, 60283-2-Ig), pSer46-P53 (CST, 2521), FOXO4 (Proteintech, 21535-1-AP), Ki-67 (D3B5) Rabbit mAb (Alexa Fluor 647 Conjugate) (CST, 12075), P21 (CST, 14074), -H2AX (Abcam, ab2254)